| scholarly article | Q13442814 |
| P2093 | author name string | Angela Coxon | |
| Karen Rex | |||
| Dongyin Yu | |||
| Ling Wang | |||
| Brad Bolon | |||
| Linh Nguyen | |||
| Grant Shimamoto | |||
| Tom Boone | |||
| James McCabe | |||
| Juan Leal | |||
| Haejin Kim | |||
| Eric Hsu | |||
| Stephen Kaufman | |||
| Richard Kendall | |||
| Robert Radinsky | |||
| Sean Caenepeel | |||
| David Cordover | |||
| Eunju Hurh | |||
| Juan Estrada | |||
| Paul Hughes | |||
| Donald M. McDonald | |||
| Hosung Min | |||
| Russell Cattley | |||
| Luke Li | |||
| James Bready | |||
| Ji-Rong Sun | |||
| Anthony Ndifor | |||
| Seog Joon Han | |||
| Shao Xiong Wang | |||
| Tani Ann Lee | |||
| Mark L. Michaels | |||
| Isaac J. Hayward | |||
| Beverly L. Falcón | |||
| Jonathan D. Oliner | |||
| P2860 | cites work | Isolation of angiopoietin-1, a ligand for the TIE2 receptor, by secretion-trap expression cloning | Q24310148 |
| Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis | Q24313372 | ||
| Angiopoietin-2 is related to tumor angiogenesis in gastric carcinoma: possible in vivo regulation via induction of proteases | Q73698344 | ||
| Inhibition of angiopoietin-1 expression in tumor cells by an antisense RNA approach inhibited xenograft tumor growth in immunodeficient mice | Q74826134 | ||
| Direct intramuscular injection of plasmid DNA encoding angiopoietin-1 but not angiopoietin-2 augments revascularization in the rabbit ischemic hindlimb | Q77531923 | ||
| Inhibition of interleukin-1 but not tumor necrosis factor suppresses neovascularization in rat models of corneal angiogenesis and adjuvant arthritis | Q78387189 | ||
| Randomized, double-blind, placebo-controlled phase II study of AMG 386 combined with weekly paclitaxel in patients with recurrent ovarian cancer | Q83069293 | ||
| Contrasting actions of selective inhibitors of angiopoietin-1 and angiopoietin-2 on the normalization of tumor blood vessels | Q24644150 | ||
| Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis | Q28300359 | ||
| Suppression of angiogenesis and tumor growth by selective inhibition of angiopoietin-2 | Q28570936 | ||
| Angiopoietin 2 stimulates migration and tube-like structure formation of murine brain capillary endothelial cells through c-Fes and c-Fyn | Q28591570 | ||
| Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy | Q29547379 | ||
| Ranibizumab for neovascular age-related macular degeneration | Q29617549 | ||
| Expression and function of angiopoietin-1 in breast cancer. | Q30940051 | ||
| Orchestration of angiogenesis and arteriovenous contribution by angiopoietins and vascular endothelial growth factor (VEGF). | Q34032032 | ||
| Inhibition of vascular endothelial growth factor (VEGF) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts | Q35102889 | ||
| Anticancer strategies involving the vasculature: vascular targeting and the inhibition of angiogenesis | Q35167341 | ||
| Pericyte recruitment in human corneal angiogenesis: an ultrastructural study with clinicopathological correlation | Q35590445 | ||
| Expression of angiogenesis stimulators and inhibitors in human thyroid tumors and correlation with clinical pathological features | Q35787996 | ||
| Activation of the tie2 receptor by angiopoietin-1 enhances tumor vessel maturation and impairs squamous cell carcinoma growth | Q35788937 | ||
| Tie receptors and their angiopoietin ligands are context-dependent regulators of vascular remodeling | Q36286583 | ||
| The dynamic roles of angiopoietins in tumor angiogenesis | Q36429528 | ||
| The duality of angiogenesis: implications for therapy of human disease | Q36597313 | ||
| Stabilization of breast cancer xenograft tumour neovasculature by angiopoietin-1. | Q36644117 | ||
| The clinical toxicity profile of vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) targeting angiogenesis inhibitors; a review | Q36650719 | ||
| Bacteriophage display and discovery of peptide leads for drug development | Q36873986 | ||
| Vascular endothelial growth factor in eye disease | Q36929380 | ||
| Tyrosine kinase inhibitors of VEGF receptors: clinical issues and remaining questions | Q37410279 | ||
| Angiopoietin-2 expression in breast cancer correlates with lymph node invasion and short survival. | Q38454174 | ||
| Angiopoietin-2 at high concentration can enhance endothelial cell survival through the phosphatidylinositol 3'-kinase/Akt signal transduction pathway | Q38525872 | ||
| Angiopoietin-1 promotes tumor angiogenesis in a rat glioma model | Q38782979 | ||
| Host-derived angiopoietin-2 affects early stages of tumor development and vessel maturation but is dispensable for later stages of tumor growth | Q39885086 | ||
| Broad antitumor activity in breast cancer xenografts by motesanib, a highly selective, oral inhibitor of vascular endothelial growth factor, platelet-derived growth factor, and Kit receptors | Q39899613 | ||
| Angiopoietin-1 promotes LYVE-1-positive lymphatic vessel formation. | Q40459739 | ||
| VEGF couples hypertrophic cartilage remodeling, ossification and angiogenesis during endochondral bone formation | Q41672985 | ||
| Angiopoietin-1 promotes lymphatic sprouting and hyperplasia. | Q42475049 | ||
| Angiopoietin 1 promotes tumor angiogenesis and tumor vessel plasticity of human cervical cancer in mice | Q44123642 | ||
| Angiopoietin-2 is required for postnatal angiogenesis and lymphatic patterning, and only the latter role is rescued by Angiopoietin-1. | Q44166149 | ||
| A human monoclonal anti-ANG2 antibody leads to broad antitumor activity in combination with VEGF inhibitors and chemotherapy agents in preclinical models | Q44277060 | ||
| Safety, pharmacokinetics, and antitumor activity of AMG 386, a selective angiopoietin inhibitor, in adult patients with advanced solid tumors | Q44649604 | ||
| Angiopoietin/Tek Interactions Regulate MMP-9 Expression and Retinal Neovascularization | Q44654332 | ||
| Angiopoietin 1 inhibits ocular neovascularization and breakdown of the blood-retinal barrier. | Q44813024 | ||
| Pegaptanib for neovascular age-related macular degeneration | Q45206481 | ||
| Effects of gene delivery on collateral development in chronic hypoperfusion: diverse effects of angiopoietin-1 versus vascular endothelial growth factor. | Q50488625 | ||
| Angiopoietin 1 causes vessel enlargement, without angiogenic sprouting, during a critical developmental period. | Q52047064 | ||
| A simple technique for preservation of fixation-sensitive antigens in paraffin-embedded tissues | Q72051492 | ||
| The effects of angiopoietin-1 and -2 on tumor growth and angiogenesis in human colon cancer | Q73603182 | ||
| P433 | issue | 10 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | angiogenesis | Q539568 |
| P304 | page(s) | 2641-2651 | |
| P577 | publication date | 2010-10-01 | |
| P1433 | published in | Molecular Cancer Therapeutics | Q2363144 |
| P1476 | title | Context-dependent role of angiopoietin-1 inhibition in the suppression of angiogenesis and tumor growth: implications for AMG 386, an angiopoietin-1/2-neutralizing peptibody | |
| Context-Dependent Role of Angiopoietin-1 Inhibition in the Suppression of Angiogenesis and Tumor Growth: Implications for AMG 386, an Angiopoietin-1/2–Neutralizing Peptibody | |||
| P478 | volume | 9 |
Search more.